|
(Health-NewsWire.Net, April 11, 2020 ) The ongoing COVID-19 pandemic—and the worldwide reaction to it—has compelled companies to radically rethink their strategies and the way they operate. We salute the industry experts helping companies survive and sustain in this pandemic.
At MarketsandMarkets™, analysts are undertaking continuous efforts to provide analysis of the COVID-19 impact on the Oligonucleotide Synthesis Market. We are working diligently to help companies take rapid decisions by studying:
1. The impact of COVID-19 on the Oligonucleotide Synthesis Market, including growth/decline in product type/use cases due to the cascaded impact of COVID-19 on the extended ecosystem of the market.
2. The rapid shifts in the strategies of the Top 50 companies in the Oligonucleotide Synthesis Market
3. The shifting short-term priorities of the top 50 companies’ clients and their client's clients
You can request an in-depth analysis detailing the impact of COVID-19 on the Oligonucleotide Synthesis Market:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=200829350
According to the recent report “Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre Design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024", The global oligonucleotide synthesis market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7%.
Browse In Depth TOC on “Oligonucleotide Synthesis Market”
157 – Tables
42 – Figures
230 – Pages
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Therapeutic applications segment to grow at the highest CAGR during the forecast period
Based on application, the oligonucleotide synthesis market is segmented into research, diagnostic, and therapeutic applications. The therapeutic applications segment, which is further segmented into RNAi oligonucleotide-based therapies, DNA & antisense oligonucleotide-based therapies, and CpG oligonucleotide-based therapies, is estimated to witness the highest growth during the forecast period. This can primarily be attributed to the investments made by companies to explore the therapeutic applications of oligos.
Hospitals accounted for the largest share of the oligonucleotide synthesis market, by end user, in 2018
Based on end user, the oligonucleotide synthesis market is segmented into academic research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, and hospitals. Hospitals accounted for the largest share of the oligonucleotide synthesis market in 2018.
Geographical Growth Analysis:
The oligonucleotide synthesis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the oligonucleotide synthesis market majorly due to the availability of funds for research from various public- and private-sector organizations in the region and the focus of various prominent players on strengthening their presence in North America through product launches and strategic acquisitions and collaborations & agreements. Europe was the second-largest regional market for oligonucleotide synthesis in 2018.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350
Key Players:
The prominent players operating in the oligonucleotide synthesis market include BioAutomation Corporation (US), LGC Biosearch Technologies (US), Eurogentec (Belgium), GeneDesign, Inc. (Japan), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US).
MarketsandMarkets™
Mr. Sanjay Gupta
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
